Increased Expression of TGFβR2 Is Associated with the Clinical Outcome of Non-Small Cell Lung Cancer Patients Treated with Chemotherapy.
Increased Expression of TGFβR2 Is Associated with the Clinical Outcome of Non-Small Cell Lung Cancer Patients Treated with Chemotherapy.
复制标题
TGF beta R2 表达增加与接受化疗的非小细胞肺癌患者的临床结果相关
DOI：
10.1371/journal.pone.0134682
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Ma Y
中科院分区：
文献类型：
--
作者：
Han Y;Jia C;Cong X;Yu F;Cai H;Fang S;Cai L;Yang H;Sun Y;Li D;Liu J;Xie R;Yuan X;Zhong X;Li M;Wei Q;Lv Z;Fu D;Ma Y
为探讨TGFβR2表达和化疗对中国非小细胞肺癌（NSCLC）患者预后的意义，采用Oncomine数据库对308例NSCLC活检组织中TGFβ R2表达进行计算机分析，随后采用定量RT-PCR对其中42例与癌旁非肿瘤组织配对的NSCLC活检组织进行分析。我们的研究结果表明，TGFβR2的表达也增加了非小细胞肺癌活检相对于正常组织样本，并与预后不良。TGFβR2的表达与肿瘤分化程度、肺组织浸润深度、化疗等临床指标也有显著相关性。此外，低表达TGFβR2的NSCLC患者接受化疗后的总生存期（OS）和无病生存期（DFS）延长。因此，TGFβR2的高表达是NSCLC患者OS和DFS降低的重要危险因素。因此，TGFβR2是化疗的潜在预后肿瘤生物标志物。
To investigate the prognostic significance of TGFβR2 expression and chemotherapy in Chinese non-small cell lung cancer (NSCLC) patients, TGFβR2 expression NSCLC was analyzed in silico using the Oncomine database, and subsequently analyzed with quantitative RT-PCR in 308 NSCLC biopsies, 42 of which were paired with adjacent non-neoplastic tissues. Our results show that TGFβR2 expression was also increased in NSCLC biopsies relative to normal tissue samples and correlated with poor prognosis. TGFβR2 expression was also significantly correlated with other clinical parameters such as tumor differentiation, invasion of lung membrane, and chemotherapy. Moreover, overall survival (OS) and disease free survival (DFS) was increased in patients with low TGFβR2 expressing NSCLC and who had undergone chemotherapy. Thus, high expression of TGFβR2 is a significant risk factor for decreased OS and DFS in NSCLC patients. Thus, TGFβR2 is a potential prognostic tumor biomarker for chemotherapy.